GlassScriptPhysician profile
Aimee Chappell
NPI 1417312703
$5,686.12
in general payments reported to CMS, 2019-2025
31 companies · $2,925 in 2025
The $2,925 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $305 · 2022: $511 · 2023: $575 · 2024: $1,371 · 2025: $2,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,745 · Travel and Lodging: $946 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,744.99 |
| Travel and Lodging | $946.38 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,404.17 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Glaxosmithkline, LLC. | $1,375.86 | 2021-2025 | Blenrep, Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $415.28 | 2022-2025 | Livtencity, Ninlaro, Iclusig |
| Celgene Corporation | $414.88 | 2022-2025 | Reblozyl, Pomalyst, Onureg |
| Abbvie INC. | $189.54 | 2024-2025 | |
| Incyte Corporation | $184.68 | 2022-2025 | Monjuvi, Niktimvo, Pemazyre |
| Astellas Pharma US INC | $172.33 | 2024-2025 | Xospata |
| Beigene USA, INC. | $168.28 | 2021-2023 | Brukinsa |
| Genzyme Corporation | $162.20 | 2024 | |
| Novartis Pharmaceuticals Corporation | $155.51 | 2022-2025 | |
| Daiichi Sankyo INC. | $137.97 | 2024-2025 | Vanflyta |
| Legend Biotech USA INC. | $121.13 | 2024-2025 | Carvykti |
| Syndax Pharmaceuticals, INC. | $98.50 | 2025 | |
| Janssen Scientific Affairs, LLC | $94.87 | 2022-2025 | Carvykti |
| Pfizer INC. | $86.84 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $76.50 | 2024-2025 | Columvi, Lunsumio, Polivy |
| Adc Therapeutics America, INC. | $57.41 | 2024-2025 | |
| Stemline Therapeutics INC. | $44.96 | 2025 | Orserdu |
| Sanofi-Aventis U.S. LLC | $43.39 | 2024 | |
| Pharmaessentia USA Corporation | $30.02 | 2025 | Besremi |
| Taiho Oncology, INC. | $29.80 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $28.48 | 2025 | Calquence |
| Teleflex LLC | $25.80 | 2024 | Arrow |
| Emd Serono, INC. | $25.25 | 2024 | |
| Geron Corporation | $23.39 | 2025 | Rytelo |
| Pharmacyclics LLC, An Abbvie Company | $22.52 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $22.08 | 2025 | Lynozyfic |
| Viiv Healthcare Company | $20.86 | 2023 | Cabenuva |
| Merck Sharp & Dohme LLC | $19.84 | 2025 | Welireg, Keytruda |
| Genmab U.S., INC. | $18.88 | 2024 | Epkinly |
| Bard Peripheral Vascular, INC. | $14.90 | 2024 | Trek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Chappell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.